https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-10-09 / Front Immunol 2019;10:2353
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-10-09 / Front Immunol 2019;10:23532019-10-09 00:00:002020-11-30 10:24:49Dendritic Cell Vaccination in Metastatic Melanoma Turns „Non-T Cell Inflamed“ Into „T-Cell Inflamed“ Tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-08-17 / Int J Mol Sci 2019 Aug;20(16)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-08-17 / Int J Mol Sci 2019 Aug;20(16)2019-08-17 00:00:002019-08-17 00:00:00Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)2019-06-03 00:00:002020-08-26 12:15:23A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)2019-05-31 00:00:002020-05-06 15:06:09Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / Melanoma Manag 2019 May;6(2):MMT20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / Melanoma Manag 2019 May;6(2):MMT202019-05-31 00:00:002019-05-31 00:00:00Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)2019-05-31 00:00:002020-05-06 15:04:34Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-29 / Front Oncol 2019;9:436
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-29 / Front Oncol 2019;9:4362019-05-29 00:00:002022-09-29 14:03:17STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-01 / Melanoma Res. 2019 04;29(2):109-118
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-01 / Melanoma Res. 2019 04;29(2):109-1182019-04-01 00:00:002019-07-01 09:14:32Melanoma vaccines: clinical status and immune endpoints
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-780
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-7802018-11-21 00:00:002020-11-30 10:25:48Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-6702018-10-01 00:00:002018-10-01 00:00:00Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
